Akari Therapeutics (AKTX) Free Cash Flow (2014 - 2026)

Akari Therapeutics has disclosed Free Cash Flow across 9 years of filings, most recently posting -$2.5 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$2.5 million, down 15.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.9 million (down 2.33% YoY), and the FY2025 annual result was -$10.6 million, up 15.81% from the prior year.
• Free Cash Flow came in at -$2.5 million for Q1 2026 at Akari Therapeutics, up from -$3.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.5 million in Q3 2024 to a low of -$4.9 million in Q2 2024.
• The 4-year median for Free Cash Flow is -$3.0 million (2025), against an average of -$3.2 million.
• Across the five-year window, Free Cash Flow jumped 51.83% in 2024 and slumped 43.17% in 2025, its largest moves.
• Akari Therapeutics' Free Cash Flow stood at -$4.4 million in 2023, then surged by 51.83% to -$2.1 million in 2024, then plunged by 43.17% to -$3.0 million in 2025, then grew by 18.18% to -$2.5 million in 2026.
• The last three Free Cash Flow figures came in at -$2.5 million (Q1 2026), -$3.0 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.